---
title: "Starcoin Group Shares to Remain Suspended After HKEX Cites Insufficient Operations and Asset Support"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274433167.md"
description: "Starcoin Group Limited's shares will remain suspended by the Hong Kong Stock Exchange due to insufficient operations and asset support. The Listing Committee cited limited operating scale, lack of revenue, and heavy reliance on intangible assets as key concerns. The company faces unresolved issues with convertible bonds and ongoing viability uncertainties. The latest analyst rating for Starcoin Group is a Sell, with a price target of HK$0.08. Despite total assets of HK$1.1 billion, much is tied to uncertain projects, leading to significant financial challenges."
datetime: "2026-02-01T22:39:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274433167.md)
  - [en](https://longbridge.com/en/news/274433167.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274433167.md)
---

# Starcoin Group Shares to Remain Suspended After HKEX Cites Insufficient Operations and Asset Support

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Innovative Pharmaceutical Biotech ( (HK:0399) ) has issued an update.

Starcoin Group Limited has been notified by the Hong Kong Stock Exchange’s Listing Committee that it failed to maintain a sufficient level of operations and assets of adequate value to justify its continued listing, leading to a decision to uphold the suspension of trading in its shares. The committee cited the company’s limited operating scale, lack of revenue from its research and development activities, early-stage status of newer ventures such as health supplements and blockchain technology, and profit forecasts lacking strong evidence, alongside concerns over its heavy reliance on intangible assets, unresolved maturity extensions for significant convertible bonds and ongoing going-concern uncertainties, all of which raise significant questions about the viability and sustainability of the business for investors and other stakeholders.

The most recent analyst rating on (HK:0399) stock is a Sell with a HK$0.08 price target. To see the full list of analyst forecasts on Innovative Pharmaceutical Biotech stock, see the HK:0399 Stock Forecast page.

**More about Innovative Pharmaceutical Biotech**

Starcoin Group Limited, formerly known as Innovative Pharmaceutical Biotech Limited, is a Hong Kong-listed company incorporated in the Cayman Islands and continued in Bermuda, with operations that have included trading activities, research and development projects, health supplements and blockchain-related initiatives. Despite holding total assets of about HK$1.1 billion as of 30 September 2025, much of this value is tied up in intangible assets linked to projects with uncertain commercial prospects, and the group is burdened by net current liabilities largely stemming from convertible bonds.

**Average Trading Volume:** 18,495,063

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$182.1M

Find detailed analytics on 0399 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [00399.HK](https://longbridge.com/en/quote/00399.HK.md)

## Related News & Research

- [With AI able to predict disease, can we treat ageing like a ‘bug’ in the system?](https://longbridge.com/en/news/288944169.md)
- [Shanghai Junshi Biosciences Sets H Share Register Closure for 2025 AGM](https://longbridge.com/en/news/288942073.md)
- [AI search is exposing a hidden weakness in the way many brands operate](https://longbridge.com/en/news/288571538.md)
- [Aux Electric Wins Shareholder Backing for Board Changes and Capital Mandates](https://longbridge.com/en/news/288893723.md)
- [LIVE MARKETS-Hunting for bond-market bargains](https://longbridge.com/en/news/288558479.md)